Hansoh Pharma’s HS-20093 Hits OS Endpoint in Phase III Small Cell Lung Cancer Trial

The headline result is an overall survival win in a tumour type where randomized confirmations have been scarce, and the distinction that this is the first randomized Phase III to show it for a B7-H3-directed ADC is what gives the readout weight beyond one company's pipeline. It matters most for the crowded B7-H3 ADC field, where several programmes are chasing the same target and a positive OS endpoint resets the evidentiary bar competitors are measured against. The open question is whether the magnitude of benefit holds across the broader relapsed population and whether the data translate into a differentiated positioning versus existing second-line options.